Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

xiamen lp pharmaceutical co., ltd. - memantine hydrochloride (unii: jy0wd0ua60) (memantine - unii:w8o17sjf3t) - memantine hydrochloride extended-release capsules is indicated for the treatment of moderate to severe dementia of the alzheimer’s type. memantine hydrochloride extended-release capsules is contraindicated in patients with known hypersensitivity to memantine hydrochloride or to any excipients used in the formulation . risk  summary there are no adequate data on the developmental risk associated with the use of memantine hydrochloride extended-release capsules in pregnant women.  adverse developmental effects (decreased body weight and skeletal ossification) were observed in the offspring of rats administered memantine during pregnancy at doses associated with minimal maternal toxicity. these doses are higher than those used in humans at the maximum recommended daily dose of memantine hydrochloride extended-release capsules  [see  data]. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

merz australia pty ltd - 17876 - tissue reconstructive material, synthetic, fluid - radiesse injectable implant is a steam sterilised, semi-solid implant created by suspending calcium hydroxylapatite in a gel carrier consisting primarily of sterile water for injection (usp) and glycerin (usp). the gel structure is formed by adding sodium carboxymethylcellulose (usp). the gel dissipates in vivo, replaced with soft tissue growth, while the calcium hydroxylapatite remains at the injection site. the result is long-term yet non-permanent restoration and augmentation. radiesse injectable implant (part number 8071m19) is indicated for plastic and reconstructive surgery, including deep dermal and sub dermal soft tissue augmentation of the facial area, and is also intended for restoration and/or correction of the signs of facial fat loss (lipoatrophy) in people with human immunodeficiency virus.

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

merz north america, inc. - botulinum toxin type a (unii: e211kpy694) (botulinum toxin type a - unii:e211kpy694) - botulinum toxin type a 50 [usp'u] - xeomin is indicated for the treatment of chronic sialorrhea in patients 2 years of age and older. upper limb spasticity in adult patients xeomin is indicated for the treatment of upper limb spasticity in adult patients. upper limb spasticity in pediatric patients, excluding spasticity caused by cerebral palsy xeomin is indicated for the treatment of upper limb spasticity in pediatric patients 2 to 17 years of age, excluding spasticity caused by cerebral palsy. xeomin is indicated for the treatment of cervical dystonia in adult patients. xeomin is indicated for the treatment of blepharospasm in adult patients. xeomin is indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients. xeomin is contraindicated in patients with: - known hypersensitivity to any botulinum toxin product or to any of the components in the formulation [see warnings and precautions (5.3) and description (11)] . - infection at t

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

merz pharmaceuticals, llc - botulinum toxin type a (unii: e211kpy694) (botulinum toxin type a - unii:e211kpy694) - botulinum toxin type a 50 [usp'u] - xeomin is indicated for the treatment of chronic sialorrhea in patients 2 years of age and older. upper limb spasticity in adult patients xeomin is indicated for the treatment of upper limb spasticity in adult patients. upper limb spasticity in pediatric patients, excluding spasticity caused by cerebral palsy xeomin is indicated for the treatment of upper limb spasticity in pediatric patients 2 to 17 years of age, excluding spasticity caused by cerebral palsy. xeomin is indicated for the treatment of cervical dystonia in adult patients. xeomin is indicated for the treatment of blepharospasm in adult patients. xeomin is indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients. xeomin is contraindicated in patients with: - known hypersensitivity to any botulinum toxin product or to any of the components in the formulation [see warnings and precautions (5.3) and description (11)] . - infection at t

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

merz australia pty ltd - 62574 - dermal tissue reconstructive material, synthetic mineral, anaesthetic - radiesse (+) lidocaine injectable implant is a sterile semi solid implant of suspended synthetic calcium hydroxylapatite in a gel carrier of sterile water for injection, glycerin, sodium carboxymethylcellulose, and 0.3% lidocaine. the gel is dissipated in vivo and replaced with soft tissue growth, while the calcium hydroxylapatite remains at the site of injection. pack contains 1 sterile 0.8ml or 1.5ml syringe and 2 sterile 27g 0.75" needles. radiesse (+) lidocaine injectable implant is indicated for plastic / reconstructive procedures, including deep dermal and subdermal soft tissue augmentation of the facial area and is also intended for restoration and correction of fat or volume loss (lipoatrophy) in the facial area and for rejuvenation of the hands.

Malaysia - Englisch - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

summit company (malaysia) sendirian berhad - amantadine sulphate -

Malta - Englisch - Medicines Authority

merz pharmaceuticals gmbh eckenheimer landstrasse 100, d-60318 frankfurt am main, germany - heparin sodium, extractum cepae, allantoin - gel - heparin sodium 5000 iu extractum cepae 10 g allantoin 1 g - preparations for treatment of wounds and ulcers

Malaysia - Englisch - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

tt medical management sdn bhd - l-ornithine-l-aspartate -

Malta - Englisch - Medicines Authority

merz pharmaceuticals gmbh eckenheimer landstrasse 100, d-60318 frankfurt am main, germany - botulinum toxin, type a - powder for solution for injection - botulinum toxin type a 50 u - muscle relaxants